KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases.